Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.71 |
| ▸ | MMP2 | P08253 | 2/20 | 0.71 |
| ▸ | CA1 | P00915 | 1/20 | 0.71 |
| ▸ | MMP1 | P03956 | 1/20 | 0.71 |
| ▸ | MMP9 | P14780 | 1/20 | 0.71 |
| ▸ | MMP8 | P22894 | 1/20 | 0.71 |
| ▸ | MMP13 | P45452 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | CA5A | P35218 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | F2 | P00734 | 3/20 | 0.64 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.64 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.64 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | DDX3X | O00571 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15619039 | 0.98 | CA2 (0.69) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL13590904 | 0.86 | CA2 (0.75) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL4495753 | 0.83 | CA2 (0.71) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL1700168 | 0.83 | CA2 (0.71) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL922350 | 0.83 | CA2 (0.71) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL12000920 | 0.83 | CA2 (1.00) | CA2MMP2CA1MMP1MMP9 | |
| Dinsed SCHEMBL1814194 | 0.81 | KMT2A (1.00) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL189037 | 0.80 | CA2 (1.00) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL6400928 | 0.80 | CA2 (1.00) | CA2MMP2CA1MMP1MMP9 | |
| SCHEMBL31527772 | 0.80 | CA2 (1.00) | CA2MMP2CA1MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4121421-B1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| CN-119241481-A | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20240382457-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS PHARMA AG (CH) | 2024-11-21 | — | — | US | disclosed |
| CN-115298170-B | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | 诺华股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-12083101-B2 | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| EP-4121421-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | Novartis AG (CH) | 2023-01-25 | — | — | EP | disclosed |
| CN-109232362-B | Aromatic heterocyclic derivative and application thereof in medicines | 广东东阳光药业有限公司 | 2022-12-27 | — | — | CN | disclosed |
| US-20210299100-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS PHARMA AG (CH) | 2021-09-30 | — | — | US | disclosed |
| WO-2021186324-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2021-09-23 | — | — | WO | disclosed |
| CN-107141254-B | A kind of preparation method of 5- sulfonyloxy -8- amide groups quinoline | 中国药科大学 | 2019-08-13 | — | — | CN | disclosed |
| US-7767721-B2 | soft agglomerates formed via reducing cuprous carboxyl compound in aqueous solution, with hydrazine; colloids; for electroconductive pastes, ink, and inkjet inks | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2010-08-03 | — | — | US | disclosed |
| WO-2010074586-A1 | PYRAZOLO[1,5-A]PYRIDINE AND IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-07-01 | — | — | WO | disclosed |
| US-7674401-B2 | Method of producing a thin conductive metal film | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2010-03-09 | — | — | US | disclosed |
| EP-1845083-A2 | New arylsulfonohydrazide inhibitors of enzymes MurC and MurD | UNIVERZA V LJUBLJANI, FAKULTETA ZA FARMACIJO (SI) | 2007-10-17 | — | — | EP | disclosed |
| US-20060098065-A1 | Copper oxide ultrafine particle | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2006-05-11 | — | — | US | disclosed |
| EP-1320523-B1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER LAMBERT CO (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20050069648-A1 | Metal oxide dispersion | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2005-03-31 | — | — | US | disclosed |
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| EP-1320523-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Warner-Lambert Company LLC (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002024672-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12083101-B2 | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | YAP1, TEAD3, TEAD2 | CA2 3089/4885MMP2 3083/4885CA1 4828/4885 |
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | BCAT1, BCAT2, ABAT | CA2 1859/4885MMP2 2563/4885CA1 2034/4885 |
| US-20240382457-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | YAP1, TEAD3, TEAD2 | CA2 3089/4885MMP2 3083/4885CA1 4828/4885 |
| US-20210299100-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | YAP1, TEAD3, TEAD2 | CA2 3079/4885MMP2 3170/4885CA1 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.